Pharmacokinetics and tissue distribution of olanzapine in rats

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 8, 1999, Pages 369-377

  Aravagiri, Manickam ^a,b   Teper, Yaroslav ^a   Marder, Stephen R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Psychopharmacology Unit   (United States)

Author keywords

Brain plasma level relationship; HPLC ECD; Olanzapine; Pharmacokinetics; Rat; Regional brain distribution; Tissue distribution

Indexed keywords

OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG LIVER LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; NONHUMAN; RAT; SPLEEN; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; HALF-LIFE; INJECTIONS, INTRAPERITONEAL; MALE; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0033361056     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6     Document Type: Article

References (22)

1. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999; 156: 286-293.
2. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-928.
3. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999; 141: 175-181.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
5. Schotte A, Jansssen PFM, Gommeren W, Luyten WHML, Van Compel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996; 124: 57-73.
6. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-1410.
7. Tollefson GD, Beasley Jr CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-465.
8. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacology 1997; 17: 472-477.
9. Beasley Jr CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine HGAP study group. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-167.
10. Kassahun K, Mattiuz E, Nyhart Jr E, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997; 25: 81-93.
11. Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A, Hotten T, Kassahun K. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos 1997; 25: 573-583.
12. Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit 1997; 19: 307-313.
13. Sunderland T, Cohen BM. Blood to brain distribution of neuroleptics. Psychiatry Res 1986; 20: 299-305.
14. Tsuneizumi T, Babb SM, Cohen BM. Drug distribution between blood and brain as a determinant of antipsychotic drug effects. Biol Psychiatry 1992; 32: 817-824.
15. Aravagiri M, Marder SR., Yuwiler A, Midha KK, Kula NS, Baldessarini RJ. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995; 13: 235-247.
16. Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology 1998; 139: 356-363.
17. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993; 9: 117-124.
18. Cohen BM, Tsuneizumi T, Baldessarini RJ, Campbell A, Babb SM. Differences between antipsychotic drugs in persistence of brain levels and behavioral effects. Psychopharmacology 1992; 108: 338-344.
19. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study. J Clin Psychiatry 1992; 52: 346-347.
20. 14C]Olanzapine in male Fisher 344 and female CD rats following single oral dose administration. Arzneim.-Forsch/Drug Res 1998; 48: 446-454.
21. Cools AR, Prinssen EPM, Ellenbroek BA. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 1996; 119: 428-439.
22. Mannens G, Meuldermans W, Snoeck E, Heykants J. Plasma protein binding of risperidone and its distribution in blood. Psychopharmacology 1994; 114: 566-572.